Glucotrack, Inc. (NASDAQ: GCTK) has completed a bridge financing following its business combination with Lōkahi Therapeutics, the company announced July 17, 2026, based in Rutherford, N.J.

E.F. Hutton & Co. served as exclusive financial advisor and placement agent for the bridge financing. The firm will continue to advise the company as it evaluates additional financing opportunities.

The business combination between Glucotrack and Lōkahi was announced July 14, 2026. Lōkahi is a clinical-stage biopharmaceutical company focused on non-opioid biologic therapies.

"The successful completion of this bridge financing represents an important step in our broader strategic plan," said Erik Emerson, Chief Executive Officer of Glucotrack. "We appreciate the support and guidance of E.F. Hutton & Co. as we complete the integration of Glucotrack and Lōkahi and evaluate additional capital formation opportunities."

Lōkahi is also advancing a program called the ai² Futures Lab, which uses university partnerships to identify clinical assets described as distressed, shelved, under-prioritized, or abandoned, with student teams conducting assessments before opportunities are considered for intake by Lōkahi.

"Lōkahi has established a differentiated strategy that combines clinical-stage biotechnology development with a disciplined approach to identifying and unlocking value from strategic opportunities, now anchored within Glucotrack's publicly listed platform," said Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co.

Glucotrack said it expects to provide additional information regarding the combined company's strategic initiatives and potential financing activities in accordance with applicable securities laws. No financial terms of the bridge financing were disclosed.